• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Future of GLP-1RAs in Obesity Treatment: Expert Perspective

Commentary
Video

With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

The future of glucagon-like peptide-1 (GLP-1) receptor agonists in obesity treatment holds significant promise, though current challenges such as supply shortages, cost, and insurance coverage persist. The long-term success of GLP-1 receptor agonists hinges on a multifaceted approach that incudes lifestyle interventions, medication adherence, and addressing weight bias and stigma, according to Michael Crotty, MD, a general practitioner who specializes in obesity medicine and is co-founder of My Best Weight in Dublin, Ireland. He explains in the short video above.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
© 2024 MJH Life Sciences

All rights reserved.